

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yvonne Lange
Title: A PHARMACOLOGIC METHOD
OF LOWERING CHOLESTEROL
PRODUCTION
Appl. No.: 10/599,898
International 04/13/2005
Filing Date:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 50-2350.

Respectfully submitted,

Dated: January 11, 2007

FOLEY & LARDNER LLP
Customer Number: 23524
Telephone: (608) 258-4303
Facsimile: (608) 258-4258

By Joseph P. Meara

Joseph P. Meara
Attorney for Applicant
Registration No. 44,932

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 11, 2007 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/599,898
				Filing Date	October 12, 2006
				First Named Inventor	Yvonne Lange
				Group Art Unit	
				Examiner Name	Unassigned
				Attorney Docket Number	047940-0280
Sheet	1	of	3		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		2003/0082617		Rothblat, et al.	5/1/2003	
		2004/0022883		Brovelli, et al.	2/5/2004	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	
			T ⁶
		Chen et al. Gastroenterology (1999) 116(3):678-85.	
		Christian, et al., J Lipid Res. 1997 Nov.; 38(11):2264-72.	
		Christian, et al., J Lipid Res. 1999 Aug.; 40(8):1475-82.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 11, 2007 <i>(use as many sheets as necessary)</i>		Application Number	10/599,898
		Filing Date	October 12, 2006
		First Named Inventor	Yvonne Lange
		Group Art Unit	
		Examiner Name	Unassigned
Sheet	2	of	3
		Attorney Docket Number	047940-0280

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		Duncan JL, Buckingham L. Resistance to streptolysin O in mammalian cells treated with oxygenated derivatives of cholesterol. Cholesterol content of resistant cells and recovery of streptolysin O sensitivity. <i>Biochim Biophys Acta</i> , (1980) 603, 278-87.	
		Gilbert RJ, Pore-forming toxins. <i>Cell Mol Life Sci</i> 2002 May; 59(5) 832-44.	
		Heuck, et al., <i>J. Biol Chem.</i> 2003 August 15; 278(33); 31218-25.	
		Klein, et al., <i>Biochemistry</i> , 1995 Oct. 24; 34(42):13784-93.	
		Kowalczyk et al. <i>Anal Biochem.</i> 1997 Feb 1; 245(1):28-37.	
		Lange Y, Matthies H, Steck TL. Cholesterol oxidase susceptibility of the red cell membrane. <i>Biochim Biophys Acta</i> , (1984) 769, 551-62.	
		Lange Y, Steck TL. The role of intracellular cholesterol transport in cholesterol homeostasis. <i>Trends in Cell Biology</i> , (1996) 6, 205-08.	
		Lange Y, Ye J, Rigney M, Steck TL. Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. <i>J. Lipid Res.</i> , (1999) 40, 2264-70.	
		Lange Y, Ye J, Steck TL. How cholesterol homeostasis is regulated by plasma membrane cholesterol in excess of phospholipids. <i>Proc. Natl. Acad. USA</i> , (2004) 101, 11664-67.	
		Lange, "Tracking Cell Cholesterol with Cholesterol Oxidase," <i>Journal of Lipid Research</i> , 1992, Vol. 33, pp. 315-321.	
		Mukherjee et al., <i>Biphs. J.</i> 1998 Oct;75(4): 1915-25.	
		Norman AW, Spielvogel AM, Wong RG. Polyene antibiotic-sterol interaction. <i>Adv. Lipid Res.</i> , (1976) 14, 127-70.	
		Radhakrishnan A, McConnell HM. Chemical activity of cholesterol in membranes. <i>Biochemistry</i> , (2000) 39, 8119-24.	
		Radhakrishnan, et al., "Condensed Complexes, Rafts, and the Chemical Activity of Cholesterol Membranes," <i>Proc. Natl Acad Sci</i> , 97(23), November 7, 2000, 12422-12427.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 11, 2007 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/599,898
				Filing Date	October 12, 2006
				First Named Inventor	Yvonne Lange
				Group Art Unit	
				Examiner Name	Unassigned
				Attorney Docket Number	047940-0280
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		Ramachandran, et al., Nat Struct Biol. 2002 Nov; 9(11):823-7	
		Rothblat, et al., J Lipid Res. 1999 May; 40(5):781-96.	
		Schmitt, et al., Emerg Infect Dis 1999 Apr-Jun; 5(2): 224-34.	
		Simons K, Ikonen E. How cells handle cholesterol. Science, (2000) 290, 1721-6.	
		Steck TL, Ye J, Lange Y. Probing red cell membrane cholesterol movement with cyclodextrin. Biophys. J., (2002) 83, 2118-25.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.